Instituto de Medicina Molecular, Cenix BioScience GmbH, and Alnylam Pharmaceuticals Discover New Targets in Malaria Infection with RNAi Technology
Published: Nov 11, 2008
CAMBRIDGE, Mass. & DRESDEN, Germany--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Cenix BioScience GmbH, a leading RNAi-focused contract research organization, today announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work resulted from an ongoing malaria research program started as a collaboration announced in 2005 between the group of Dr. Maria Mota at the Instituto de Medicina Molecular (IMM) in Portugal and Cenix, which was extended to include Alnylam’s RNAi therapeutic technology, involving scientists from both Roche Kulmbach GmbH (formerly Alnylam Europe AG), and Alnylam. The new data show the first genomics-driven identification of novel host factors involved in malaria infection and contribute toward a better understanding of host-pathogen interactions, which may help in developing new prophylactic or therapeutic strategies.